In conclusion, the present study demonstrates that the combined pharmacological treatment with an FDA-approved DNMT inhibitor and TMP269 improves muscle strength and performance in a mouse model for recessive RYR1 congenital myopathy. The gene discussed is DNMT1; the disease is congenital myopathy with cores.